Chinese Herbal Medicine as an Adjunctive Therapy Ameliorated the Incidence of Chronic Hepatitis in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study
Table 4
Hazard ratios and 95% confidence intervals of chronic hepatitis risk associated with Chinese herbal formulas used among breast cancer patients.
CHM prescription
Chronic hepatitis
Hazard ratio (95% CI)
Number of events
Crude
Adjusted†
Non-TCM user
6928
442
1 (reference)
1 (reference)
CHM user: single herb
Hedyotis diffusa
1809
104
0.68 (0.55–0.84)
0.51 (0.41–0.63)
Taraxacum officinale
2161
117
0.64 (0.52–0.78)
0.46 (0.37–0.57)
Scutellaria barbata
1416
81
0.64 (0.50–0.81)
0.47 (0.37–0.60)
Spatholobus suberectus
1640
91
0.66 (0.53–0.83)
0.48 (0.38–0.61)
Salvia miltiorrhiza
1706
110
0.71 (0.58–0.88)
0.53 (0.43–0.65)
Zizyphi Spinosi Semen
1578
84
0.60 (0.47–0.76)
0.45 (0.35–0.57)
Astragalus membranaceus
1716
111
0.74 (0.60–0.91)
0.54 (0.44–0.67)
Rhei Rhizoma
957
36
0.44 (0.32–0.62)
0.33 (0.23–0.46)
Polygonum multiflorum Thunb.
1383
81
0.68 (0.54–0.86)
0.53 (0.41–0.67)
Fritillaria thunbergii Miq.
1467
67
0.52 (0.40–0.68)
0.40 (0.31–0.52)
CHM user: formula
Jia-Wei-Xiao-Yao-San
2814
180
0.69 (0.58–0.83)
0.55 (0.46–0.65)
Xiang-Sha-Liu-Jun-Zi-Tang
1549
98
0.73 (0.58–0.91)
0.54 (0.43–0.68)
San-Zhong-Kui-Jian-Tang
879
47
0.66 (0.49–0.90)
0.50 (0.37–0.67)
Suan-Zao-Ren-Tang
1253
69
0.62 (0.48–0.80)
0.48 (0.37–0.62)
Gui-Pi-Tang
1369
76
0.65 (0.51–0.83)
0.49 (0.38–0.63)
Zhen-Ren-Huo-Ming-Yin
935
36
0.45 (0.32–0.63)
0.34 (0.24–0.47)
Bu-Zhong-Yi-Qi-Tang
1356
84
0.69 (0.55–0.88)
0.53 (0.42–0.67)
Zhi-Bai-Di-Huang-Wan
1142
69
0.69 (0.53–0.88)
0.52 (0.40–0.67)
Xue-Fu-Zhu-Yu-Tang
1101
56
0.58 (0.44–0.76)
0.45 (0.34–0.59)
Sheng-Mai-Yin
1147
61
0.63 (0.48–0.82)
0.47 (0.36–0.62)
Crude represented relative hazard ratio; adjusted represented adjusted hazard ratio: mutually adjusted for Chinese herb used, age, CCI score, treatment, and lag time in Cox proportional hazard regression. Lag time was defined as the duration between first diagnosis breast cancer dates and first accepted Chinese herb medicine date during the follow-up period. ,, and .
